Methods for producing modified reverse transcriptases
US-2024124856-A1 · Apr 18, 2024 · US
Anti-Inflammatory Peptides and Composition Comprising the Same
US2017327802A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017327802-A1 |
| Application number | US-201715664806-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 31, 2017 |
| Priority date | Jul 20, 2012 |
| Publication date | Nov 16, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
First claim
Opening claim text (preview).
1 - 21 . (canceled) 22 . A cell-penetrating peptide comprising: (a) SEQ ID NO: 153; or (b) an amino acid sequence comprising at least 80% sequence identity to SEQ ID NO:153; or (c) a fragment of an amino acid sequence defined in (a) or (b). 23 . A composition comprising the cell-penetrating peptide of claim 22 . 24 . A conjugate comprising an isolated carrier peptide and an active ingredient, wherein the carrier peptide is 20 amino acids in length and consists of SEQ ID NO:153. 25 . The conjugate of claim 24 , wherein the isolated carrier peptide and the active ingredient are joined by a linker. 26 . The conjugate of claim 24 , wherein the isolated carrier peptide and the active ingredient are joined via a non-covalent bond. 27 . The conjugate of claim 24 , wherein the active ingredient is at least one selected from the group consisting of a protein, a nucleic acid, a peptide, lipid, a glycol-lipid, a mineral, a sugar, a nano-particle, a biological product, a contrast agent, a drug, and a chemical compound. 28 . The conjugate of claim 24 , wherein the active ingredient is fluorescein isothiocyanate (FITC) or Green Fluorescent Protein (GFP). 29 . The conjugate of claim 27 , wherein the contrast agent is selected from the group consisting of a radiopaque contrast agent, a paramagnetic contrast agent, a superparamagnetic contrast agent, and a CT contrast agent. 30 . The conjugate of claim 29 , wherein the contrast agent comprises iron. 31 . The conjugate of claim 29 , wherein the contrast agent comprises ferrocenecarboxylic acid. 32 . A composition comprising the conjugate according to claim 24 as an active ingredient. 33 . The composition of claim 32 , comprising 0.1 μg/mg to 1.0 mg/mg of the isolated carrier peptide. 34 . The composition of claim 32 , wherein the composition is a pharmaceutical composition formulated for oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous administration. 35 . The composition of claim 32 , wherein the composition is a cosmetic composition. 36 . The composition of claim 32 , wherein the composition is a health food composition. 37 . A method for treating or preventing a mitochondrial related disease or disorder by administering the composition according to claim 32 .
Assignees
Inventors
Classifications
Peptides; Protein hydrolysates · CPC title
- C12N9/1276Primary
RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase · CPC title
Transferases (2) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017327802A1 cover?
- The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprisi…
- Who is the assignee on this patent?
- Kim Sang Jae, Gemvax & Kael Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N9/1276. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Nov 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).